- Voyageur (VM) has completed comparative studies of SmoothX versus Readi-Cat 2 per cent
- SmoothX is intended for use in computed tomography of the abdomen and pelvis to delineate the gastrointestinal tract
- Results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75 per cent of patients, a key finding prior to market launch
- The company plans to offer 13 barium contrast product lines in Canada and the U.S.
- CEO Brent Willis spoke with Brieanna McCutcheon about the news
- Voyageur is focused on the development of barium and iodine active pharmaceutical ingredients and imaging contrast agents for the medical imaging marketplace
- Voyageur Pharmaceuticals (VM) last traded at $0.09 per share
Voyageur (VM) has completed comparative studies of SmoothX versus Readi-Cat 2 per cent.
SmoothX is intended for use in computed tomography of the abdomen and pelvis to delineate the gastrointestinal tract.
The studies included a taste test and computed tomography scans on patients.
Results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75 per cent of patients.
The computed tomography scans resulted in equivalent performance to the current drug.
A medical white paper is in the works to provide in-depth analysis of the studies and insights into the effectiveness of SmoothX for abdominal diagnostic imaging procedures.
CEO Brent Willis spoke with Brieanna McCutcheon about the news.
Voyageur is advancing the development of four additional barium contrast products, all of which have Health Canada licenses.
Voyageur plans to submit additional new generic product lines to Health Canada for product licenses, including multiple barium swallow products for the diagnosis of dysphagia. Management views this as a potential high-growth area, with dysphagia reported in up to 8 per cent of the world’s population, or almost 600 million people (National Foundation of Swallowing Disorders).
The company plans to offer 13 barium contrast product lines in Canada and the U.S.
It will hold its annual general and special meeting on June 28, 2023 at 10:00 am, at the offices of DS Lawyers Canada LLP, 333 7th Avenue SW #800, Calgary, Alberta.
Voyageur is focused on the development of barium and iodine active pharmaceutical ingredients and imaging contrast agents for the medical imaging marketplace.
Voyageur Pharmaceuticals (VM) last traded at $0.09 per share.
This is sponsored content, please see full disclaimer here.